Mink Therapeutics Inc. (INKT) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Mink Therapeutics Inc. (INKT:NASDAQ), powered by AI.

Current Price
$11.81
P/E Ratio
-4.0
Market Cap
50M
Sector
Healthcare
What is the Mink Therapeutics Inc. stock price forecast?

Mink Therapeutics Inc. is currently trading at $11.81. View real-time AI analysis on Alpha Lenz.

What is Mink Therapeutics Inc. insider trading activity?

View the latest insider trading data for Mink Therapeutics Inc. on Alpha Lenz.

What is Mink Therapeutics Inc.'s P/E ratio?

Mink Therapeutics Inc.'s P/E ratio is -4.0.

Mink Therapeutics Inc.

NASDAQ · INKT
$11.81-0.72(-5.78%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Mink Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Mink Therapeutics Inc. trades at a P/E of -4.0 (undervalued) with strong ROE of 73.9%.

Ask for details

Company Overview

Mink Therapeutics Inc. is a biotechnology company that focuses on developing innovative immunotherapy treatments for cancer and infectious diseases. The primary function of Mink Therapeutics is to harness the power of the body's immune system to target and eliminate malignant cells or pathogens, potentially providing new avenues for treating challenging medical conditions. A notable feature of the company includes its proprietary platforms that engineer allogeneic, non-genetically modified, and cell-based therapies aimed at enhancing immune responses. Mink Therapeutics operates within the broader biotechnology and healthcare sector, a dynamic industry characterized by rapid advancements and significant investments driven by the demand for novel therapeutic solutions. Given its focus on cutting-edge research and development, Mink Therapeutics Inc. plays a vital role in the pharmaceutical landscape by contributing to the pool of potential future therapies that can address unmet medical needs, therefore holding significant promise and relevance in the ever-evolving field of medical innovation.

CEODr. Jennifer S. Buell Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees23

Company Statistics

FY 2025

Profile

$50.43MMarket Cap
$0.00Revenue
0.00Shares Out
23Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-4.04P/E
-3.54P/B
N/AEV/Sales
-3.48EV/EBITDA
-8.51P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-125.20%ROA
73.90%ROE
-125.13%ROIC

Financial Health

$13.36MCash & Cash Equivalents
$15.11MNet Debt
-200.08%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Mink Therapeutics Inc. (ticker: INKT) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 23 employees. Market cap is $50M.

The current price is $11.81 with a P/E ratio of -4.04x and P/B of -3.54x.

ROE is 73.90%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Mink Therapeutics Inc. (INKT) Stock Forecast 2026 $11.81 — Price, Financials & Analyst Targets | Alpha Lenz